I don’t think we need to assume it’s inventory. The first PR on the first 25m specifically spelled out manufacturing but the second one didn’t. Could be loading up on cash for cancer trials . I would expect we get breakthru drug recognition based on the results to date. Since Dr Kelly sees us as an oncology company I doubt if we would use license and sales agreements in that area along with cash from a BP to assist with those trials. But anything we have which is currently in progress that isn’t oncology is probably fair game for outside help and licensing.
So perhaps the latest investment is earmarked for the shift to oncology efforts